The search of new and readily accessible dual inhibitors of DYRK1A and CLK1, two kinases involved at different levels in the formation of amyloid plaques and neurofibrillary tangles in AD patients, remains a challenge in the development of new drug candidates in AD treatment. Here, DYRK1A is linked to Alzheimer disease.